1
|
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol 2018; 20:1631-1632. [DOI: 10.1007/s12094-018-1956-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
2
|
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol 2017; 20:862-869. [PMID: 29178019 DOI: 10.1007/s12094-017-1797-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 11/05/2017] [Indexed: 11/28/2022]
Abstract
INTRODUCTION This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving anti-estrogen therapy in clinical practice, getting real-world data. MATERIALS AND METHODS Multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile. RESULTS A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and ≥ 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2- patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequently adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%). CONCLUSIONS Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.
Collapse
Affiliation(s)
- I Blancas
- Hospital Universitario Clínico San Cecilio, Complejo Hospitalario Universitario, C/Dr. Oloriz, 16, 18012, Granada, Spain.
| | - M Fontanillas
- Hospital Clinic de Barcelona, illarroel, 170, 08036, Barcelona, Spain
| | - V Conde
- Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas, S/N, 18014, Granada, Spain
| | - J Lao
- Hospital Universitario Miguel Servet, Paseo Isabel la Católica, 1-3, 50009, Zaragoza, Spain
| | - E Martínez
- Hospital Provincial de Castellón, Av. del Dr. Clarà, 19, 12002, Castelló de la Plana, Spain
| | - M J Sotelo
- Hospital Universitario Clínico San Carlos, C/del Profesor Martín Lagos, s/n, 28040, Madrid, Spain
| | - A Jaen
- Hospital de Jaén, Avda. del Ejército Español, nº 10, 23007, Jaén, Spain
| | - J L Bayo
- Hospital Juan Ramón Jiménez, Ronda Exterior Norte s/n, 21005, Huelva, Spain
| | - F Carabantes
- Hospital Universitario Carlos Haya, Av. de Carlos Haya, s/n, 29010, Málaga, Spain
| | - J J Illarramendi
- Complejo Universitario Hospital de Navarra, Calle Irunlarrea, 3, 31008, Pamplona, Spain
| | - M M Gordon
- Hospital de Jerez, Ronda de Circunvalación s/n, 11407, Cádiz, Spain
| | - J Cruz
- Hospital Universitario de Canarias, Carretera de Ofra, s/n, 38320, Santa Cruz de Tenerife, Spain
| | - A García-Palomo
- Complejo Universitario Asistencial de León, C/Altos de Nava, s/n, León, Spain
| | - C Mendiola
- Hospital Universitario, 12 de Octubre, Avenida de Córdoba, s/n, 28041, Madrid, Spain
| | - E Pérez-Ruiz
- Hospital Costa del Sol, Autovia A-7, Km 187, 29603, Marbella, Spain
| | - J S Bofill
- Hospital Nuestra Señora De Valme, Av. de Bellavista, s/n, 41014, Seville, Spain
| | - J M Baena-Cañada
- Hospital Universitario Puerta del Mar, Av. Ana de Viya, 21, 11009, Cádiz, Spain
| | - N M Jáñez
- Hospital Ramón y Cajal, Ctra. de Colmenar Viejo, km. 9,100, 28034, Madrid, Spain
| | - G Esquerdo
- Clínica Benidorm, Av. Alfonso Puchades, 03501, Benidorm, Spain
| | - M Ruiz-Borrego
- Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013, Seville, Spain
| |
Collapse
|
3
|
Blancas I, Fontanillas M, Conde Herrero V, Lao J, Martinez de Dueñas E, Sotelo Lezama M, JaÉn-Morago A, Bayo J, Carabantes F, Illaramendi J, Gordón M, Ruiz-Borrego M, Cruz J, García-Palomo A, Mendiola C, Perez-Ruiz E, Cañada JB, Martínez N, Esquerdo G, Bofill JS. Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Aparisi F, Garcia Sanchez J, Sanchez-Hernandez A, Giner V, Muñoz-Langa J, Esquerdo G, López Jiménez A, Garde J, Juan Vidal O. A multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Esquerdo G, Cervera JM, Barrajon E, Juarez A, Llorca C, Diaz N, Lopez A, Peiro R, Diez L. Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors: Pronost study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Llorca C, Esquerdo G, Muñoz J, Sanchez-Hernandez A, Gómez-Codina J, Juan Vidal O, Maciá S, Catot S, Giner V, Aparisi F. Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in elderly non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Giner V, Juan Vidal O, Muñoz J, Esquerdo G, Sanchez-Hernandez A, Gómez-Codina J, Aparisi F, Maciá S, López Jiménez A, Catot S. Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in non-small cell lung cancer (NSCLC) patients with ECOG performance status 2. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Lopez Jimenez A, Esquerdo G, Barrajon E, Del Rio Pazos L, Cervera J, Diaz N, Angeles Oyonarte C. Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Esquerdo G, Cervera J, Barrajon E, Juarez A, Llorca C, Diaz N, Lopez A, Peiro R. Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors (Pronost Study). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Pazo Cid RA, Esquerdo G, Puertolas T, Calderero V, Gil I, Lao J, Millastre E, Alvarez-Alejandro M, Madani J, Anton A. Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14619] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Cervera Grau J, Gonzalez-Billalabeitia E, Lopez A, Juanidal O, Satre J, Barrajon E, Esquerdo G, Molins C, Maciá S, Rolfo CD. Diverse long-time progression-free survival (PFS) and overall survival (OS), based on metastasis location, in metastatic urothelial carcinoma (MUC) patients treated with pemetexed (P) in monotherapy: Results from a longer follow-up of Arco del Mediterraneo Group. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Barrajon E, Lopez A, Esquerdo G, Cervera JM. Cure rate in early colorectal cancer estimated from disease-free survival curves from phase III comparative clinical trials: Necessity of long follow-up. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15006 Background: The traditional end point for adjuvant clinical trials is overall survival (OS). Short-term disease-free survival (DFS) has been accepted as a surrogate of 5-year OS in colorectal cancer trials. Nevertheless, recent adjuvant trials have not shown a consistent improvement in OS despite a significant improvement in DFS. Two reasons may explain this effect: 1) a delay in relapse produced by treatment, not affecting the cure rate, or 2) more effective treatments in relapsing patients which delay death, hiding a real difference in cure rates. The aim of this project is to study the relationship between DFS and OS in trials of early colorectal cancer. Methods: Phase III comparative trials in colorectal cancer were searched in databases and cancer meetings. Trials were split to build and validate the model. United States 2000 population life table data were obtained from Berkeley Mortality Database. Survival curves were modelled according to a cured fraction following a Weibull distribution and a relapsing fraction following a binomial distribution. DFS was modelled as time to a single event and OS was modelled as time to two events. Cured fraction was estimated and odds ratio (OR) with 95% confidence interval was calculated for experimental arms. Time to achieve a plateau in DFS was estimated as the curve point with a risk of relapse below 1%. Regression analysis between DFS and OS was performed for different intervals of follow up. Results: Thirty six study arms reporting DFS were analyzed to build the model. The model is consistent with an annual event rate of 0.33. DFS curves with this event rate predict a mean cure rate of 0.58 (range: 0.11–0.73). Estimated time to achieve a plateau in DFS is 9.3 years (range: 8.3–11.2 years). Significance of OR is coherent with hazard ratio reported in the studies. Trials finished after 1999 show more OS related to DFS. Regression analysis between DFS and OS show changing parameters at different intervals of follow up and some non-linearities. Trial validation, and analysis with trials reporting relapse free survival will be presented. Conclusions: Follow up of up to 10 years in colon adjuvant trials appears to be appropriate to reliably detect benefit in OS instead of a delay effect on relapse. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Barrajon
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Clinico Universitario San Juan, San Juan de Alicante, Spain
| | - A. Lopez
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Clinico Universitario San Juan, San Juan de Alicante, Spain
| | - G. Esquerdo
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Clinico Universitario San Juan, San Juan de Alicante, Spain
| | - J. M. Cervera
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Clinico Universitario San Juan, San Juan de Alicante, Spain
| |
Collapse
|
13
|
Esquerdo G, Doménech M, Bermejo JC, López P, Pedro C, Villadiego K, Constenla M, Sánchez-Rovira P, Gasquet JA, Rodríguez CA. Final results of a prospective, observational study of the effectiveness of darbepoetin alfa administered every three weeks for the treatment of chemotherapy-induced anaemia in elderly patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20654 Background: Cancer incidence is increasing in elderly but specific treatment data in this population is not often available. The objectives of this study were to evaluate the effectiveness and safety of darbepoetin alfa (DA) administered once every 3 weeks (Q3W) for the treatment of chemotherapy-induced anaemia (CIA) in elderly within routine clinical practice. Methods: Prospective, observational, single-arm, multicentre study performed in 28 centres across Spain. Eligible patients (pts):≥65 years, anaemic (haemoglobin [Hb] 11 g/dl), with non-myeloid malignancies, and scheduled to receive ≥9 weeks (wks) of chemotherapy. Pts were treated with a fixed dose of DA 500 μg Q3W and treatment stopped if Hb levels exceeded 13g/dl. Primary endpoint was hematopoietic response (Hb increase ≥2g/dl or Hb ≥12g/dl without transfusions in the previous 28 days). Secondary endpoints included percentage of pts achieving target Hb (>11g/dl from wk 5 till end of treatment without red blood cell transfusion within 28 days), changes in the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) scale and the incidence of adverse reactions. Results: Data were prospectively collected from 153 pts: women (56.86%), mean (SD) age 73.43 (5.77) years, ECOG Performance Status 0–1 (65.36%) with solid tumors (66.67%) and lymphoproliferative malignancies (33.33%) and stage III/IV (63.40%). Most pts (90.20%) had baseline Hb levels between 9–11g/dL. DA was administered for a median of 9.0 wks (range: 1–22.57). The Kaplan-Meier percentage (KM; 95% CI) of pts who achieved hematopoietic response was 69.70% (56.06–83.34) and 72.22% (57.5–86.94) for pts who achieved target Hb (>11g/dL). FACT-F median score at baseline was 29.00 and 33.00 at the end of the study. Only one (0.7%) non-serious adverse reaction (cutaneous eruption) was reported. Conclusions: These results suggest that DA given at 500 μg Q3W to elderly pts with non-myeloid malignancies is an effective and well-tolerated treatment for CIA. [Table: see text]
Collapse
Affiliation(s)
- G. Esquerdo
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - M. Doménech
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - J. C. Bermejo
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - P. López
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - C. Pedro
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - K. Villadiego
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - M. Constenla
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - P. Sánchez-Rovira
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - J. A. Gasquet
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| | - C. A. Rodríguez
- Clinica Benidorm, Barcelona, Spain; Althaia, Barcelona, Spain; H. Sagrat Cor, Barcelona, Spain; H. Virgen de las Nieves, Granada, Spain; H. del Mar, Barcelona, Spain; H. de Pontevedra, Pontevedra, Spain; H. Jaén, Jaén, Spain; Amgen, S.A., Barcelona, Spain; H. Universitario de Salamanca, Salamanca, Spain
| |
Collapse
|
14
|
Castañón C, Alonso V, Vieitez J, Esquerdo G, Pérez-Carrión R, Belda-Iniesta C, Rubio M, Roca J, García G, Salut A. Clinical profile of patients with metastatic colorectal adenocarcinoma treated with bevacizumab in first-line: AVATRAN study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, LLorca C, Pérez E, Cervera Grau J, Ramos M. Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Esquerdo G, Llorca C, Cervera J, Juarez A, Orts D, Carrato A. 1144 POSTER Comparison of two questionnaires assessing fatigue in patients with chemotherapy-induced anaemia treated with darbepoetin alfa every 3 weeks. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70663-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
17
|
Galan A, del Barco S, Mendez M, Esquerdo G, Cerezuela P, Huarriz M, Bandres E, Paules A, Gayo J, Garcia-Foncillas J. 6562 POSTER First-line treatment with vinorelbine (VNR) plus carboplatin (CBDCA) for patients with advanced non-small-cell lung cancer (NSCLC): MAP4/OP18 mRNA expression as marker predictive of response. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71390-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
18
|
Mendez M, Andrade J, Esquerdo G, Morales S, Garcia-Gomez R, Garcia-Bueno J, Blancas I, Trujillo R, Juarez J, Gayo J. 6605 POSTER Oral vinorelbine as single-agent first-line treatment in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71433-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
19
|
Esquerdo G, Llorca C, Cervera J, Juarez A, Orts D, Carrato A. An assessment of cancer-related fatigue in patients (pts) with chemotherapy-induced anaemia (CIA) treated with darbepoetin alfa (DA): Comparison of two quality of life (QoL) questionnaires. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19654 Background: CIA is often associated with debilitating fatigue and reduced QoL. DA can effectively treat CIA when administered once every 3 weeks (Q3W).This study aims to compare the psychometrics of the Functional Assessment of Cancer Therapy Fatigue Subscale (FACT-F) and The Fatigue Symptom Inventory (FSI) in CIA pts treated with DA Q3W. Methods: Longitudinal single- centre prospective study in adult pts with solid tumours undergoing chemotherapy (CT) and with mild to moderate cancer-related fatigue (CRF) (Visual Analogue Scale (VAS) =30 mm). Pts with haemoglobin (HB) levels <11 g/dL were treated with DA 500 mcg Q3W. Key clinical parameters, FACT-F, and FSI measurements were collected at the beginning and end of the CT treatment period. Psychometric indicators for reliability and validity were calculated. Results: A preliminary analysis was conducted in 58 pts: mean age, 61.3 years (SD 12.3), 51.7% women, 25.9% with breast cancer, 91.4% ECOG 0–1, 69.0% IV stage, 63% had no prior CT. At baseline, the mean CRF score by VAS was 58.8 mm (SD 19.4) and the mean Hb was 10.2 g/dL (SD 0.7). Median CT duration was 15.1 weeks (range, 3.3 - 25.7) and all pts received DA treatment during CT (median duration of CT, 6.6 wks [range, 0 - 19]). The median number of DA doses administered was 3 (range, 1–7). The rate of hematopoietic response (Hb ≥ 12 g/dL or Hb rise from baseline ≥ 2 g/dL) was 69.0%. FACT-F and FIS scores improved by 5.6 and 13.0 points respectively during CT. Consistency (Cronbach alpha coefficient - CA) was high and similar for both questionnaires (FACT-F=0.98; FSI=0.97). Conclusions: Both the FACT-F and FIS QoL questionnaires measured a change in fatigue during the study with high and similar consistency. DA administered at a fixed dose of 500 mcg Q3W seems to be effective in clinical practice. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Esquerdo
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| | - C. Llorca
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| | - J. Cervera
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| | - A. Juarez
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| | - D. Orts
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| | - A. Carrato
- Hospital General, Elda, Spain; Hospital General, Elche, Spain
| |
Collapse
|
20
|
Galan J, del Barco S, Mendez M, Esquerdo G, Huarriz MG, Bandres E, Gil MC, Paules AB, Gayo J, Garcia- Foncillas J. MAP4/OP18 mRNA expression predicts progression in patients treated with vinorelbine plus carbolpatin in advanced lung cancer patients in a Multicenter trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14088 Background: Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. MAP4 and stahmin have been previously reported as potential markers of resistance to treatment based on microtubule-destabilizing agents. Methods: In this multicenter study, we have used quantitative PCR to analyse expression of MAP4, stathmin, beta-tubulin III, BRCA1 and ERCC1 in mRNA isolated from peripheral blood samples of 51 non-small-cell lung cancer patients treated with vinorelbine/carboplatin. Results: In a preliminary set, 29 patients with stage IIIB and IV were analyzed. Lower levels of MAP4/OP18 mRNA expression are statistically related with response to vinorelbine-based treatment (p=0,029). This significant relationship is maintained in a second analysis after third cycle of treatment (p=0,032). Higher levels of MAP4/op18 were associated with a lower TTP (p=0,05). Conclusions: Our preliminary results suggest that the ratio MAP4/OP18 may be a good predictor of response for patients with non-small-cell lung cancer treated with vinorelbine-based chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Galan
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - S. del Barco
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - M. Mendez
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - G. Esquerdo
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - M. G. Huarriz
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - E. Bandres
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - M. C. Gil
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - A. B. Paules
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - J. Gayo
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| | - J. Garcia- Foncillas
- Hospital of Sagunto, Sagunto, Spain; Hospital Josep Trueta, Girona, Spain; Hospital of Mostoles, Mostoles, Spain; Hospital of Elda, Elda, Spain; Center for Applied Medical Research, Pamplona, Spain; Pierre Fabre, Barcelona, Spain; University Clinic of Navarra, Pamplona, Spain
| |
Collapse
|
21
|
Barrajon E, Lopez A, Esquerdo G. Influence of single agent gemcitabine (GEM) schedule on the pattern of response and toxicity in patients with advanced pancreas, lung and breast carcinoma: A systematic review. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.13009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13009 Background: Dose dense chemotherapy has been advocated as a way to improve results in patients with cancer. Increasing dose (and the area under the curve of concentration-time, AUC) may increase response and toxicity, limiting clinical benefit. For phase-specific agents such as GEM, different schedules with the same dose and AUC may produce different patterns of efficacy and toxicity. Partial comparisons between schedules in clinical trials are not able to design optimal schedules. A systematic analysis of all different schedules of GEM, integrating clinical, pharmacodynamic and pharmacokinetic data in a mathematical model may provide an optimum. Methods: Clinical trials of single agent GEM in advanced pancreas, lung and breast carcinoma have been searched in PubMed, references of published clinical trials, and presentations in cancer meetings. Prognostic factors (age, sex, sex, performance status, previous chemotherapy, stage), schedule details (dose, time and frequency of infusions), response rate and toxicity (hematological, mucosal, skin and diarrhea) were analyzed in a multivariate model. In vitro data (concentration and time of exposure) and pharmacokinetic/pharmacodynamic data were included in the model, estimating the AUC above a concentration threshold (AUCt) obtained for every clinical schedule. Results: Ninety five clinical trials including 7917 patients with cancer of the pancreas (39 trials), lung (45 trials) or breast cancer (11 trials) were pooled. GEM was administered at doses of 90–2800 mg/m2 (median 1000 mg/m2) infused in 0.5–24 hours (median 0.5 h). Except for 1 schedule, treatment was repeated for 1–7 consecutive weeks (median 3) followed by a 2 week rest period. Response rate was 2.7–33.3% (median 8%) for pancreas, 0–38.5% (median 18.5%) for lung and 0–37.1% (median 20%) for breast cancer. Epithelial toxicity was inferior to hematological toxicity (grade 3/4: 0% vs 11% for leucopenia). A mathematical model was applied to 24 different schedules. Conclusions: GEM schedules in literature show great homogeneity, most of them 1000 mg/m2 for 3 consecutive weeks followed by a 2 week rest period. The model allows simulations to optimize concentration over 12 nM. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Barrajon
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Universiario de San Juan, San Juan de Alicante, Spain; Hospital de Elda, Elda Alicante, Spain
| | - A. Lopez
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Universiario de San Juan, San Juan de Alicante, Spain; Hospital de Elda, Elda Alicante, Spain
| | - G. Esquerdo
- Hospital Clinica Benidorm, Benidorm Alicante, Spain; Hospital Universiario de San Juan, San Juan de Alicante, Spain; Hospital de Elda, Elda Alicante, Spain
| |
Collapse
|
22
|
Maestu I, Muñoz J, Gómez-Aldaraví L, Esquerdo G, Yubero A, Torregrosa MD, Romero R. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine. Clin Transl Oncol 2007; 9:99-105. [PMID: 17329221 DOI: 10.1007/s12094-007-0019-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND The incidence and prevalence of comorbid conditions in lung cancer patients increase with age. The aim of the study was to determine response and tolerability with the biweekly combination gemcitabine-vinorelbine in elderly non-small-cell lung cancer (NSCLC) patients. In order to characterise the population included in the study well and assess the results achieved properly, an evaluation of the functional status, comorbidity and survival was performed. PATIENTS AND METHOD Between June 2001, and December 2003, 59 untreated advanced NSCLC patients over the age of 70 years entered the study. Treatment consisted of gemcitabine 1750 mg/m(2) and vinorelbine 30 mg/m(2) on day 1 every two weeks. The response was evaluated every f ive cycles (RECIST guidelines). Comorbidity was evaluated according to the Charlson and Kaplan Feinstein scales. To measure functional status, activities of daily living (ADL) and instrumental ADL (IADL) were considered. RESULTS Median age was 74; ECOG performance status was >2 in 59.3%; no dependence in ADL or IADL was found in 24.8% and 42.4% of patients, respectively. A total of 381 courses were administered. Grade 3-4 neutropenia was present in 6.8% of these courses and correlated with IADL. Objective response was 22% (95% CI 12-32). Mean global survival and cause-specific survival were 29 weeks (95% CI 19.9-38.1) and 32 weeks (95% CI 23.4-40.8) respectively. Comorbidity displayed no close correlation with functional status, but comorbidity according to the Kaplan Feinstein index correlated with IADL. Performance status, ADL, IADL and weight loss were significantly related to survival in multivariate analysis. CONCLUSIONS This biweekly combination is feasible in elderly lung cancer patients with a high burden of comorbidity and dependence. Toxicity is acceptable, whereas response rate and survival fall in the range of active regimens. ADL and IADL indices allow the identification of elderly patients with a worse prognosis.
Collapse
Affiliation(s)
- I Maestu
- Oncology Department, Virgen de los Lirios Hospital, Poligono de Caramanxel s/n, 03804 Alcoy, Alicante, Spain.
| | | | | | | | | | | | | |
Collapse
|
23
|
Fírvida JL, Esquerdo G, Amenedo M, Salgado M, Llorca C, González A, Pérez E, Cervera JM, Ramos M. Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17016 Background: Platinum therapy has been the backbone treatment in NSCLC. The concomitant use of platinum derivatives and taxanes has shown high antitumoral activity with moderate toxicity. To improve the therapeutic index of this combination, we performed a study with biweekly carboplatin and docetaxel. Primary objective was determination of objective response rate (ORR). Secondary objectives were time to progression, tolerability and overall survival. Methods: Patients histologically confirmed of non-small cell lung cancer, aged ≥ 18, ECOG PS 0–2, measurable lesion according RECIST criteria, adequate bone marrow, renal and hepatic function were included. Prior chemotherapy was not allowed. Patients received treatment with a combination of Docetaxel 50 mg/m2 and Carboplatin AUC-4 each 15 days for a maximum of 8 cycles. Results: Fifty patients were included between March 2004 and July 2005, 84% were male, median age was 63 years old (range 48–77), 78% had ECOG PS 0–1 and 64% of patients had stage IV. Histology was squamous cell carcinoma (54%) adenocarcinoma (36%) and large cell carcinoma (10%). A total 316 cycles were administrated (median 7, Range 1–12). Over 46 evaluable patients for response, one achieved CR, 13 PR, 21 SD and 11 PD, with an overall response rate of 30.5% (95% CI: 17.2–43.8). Median follow up of patients is 8.3 months, with a median TTP of 6.3 months and median overall survival of 11.1 months. Grade 3–4 toxicity per patient was: neutropenia (22.0%), asthenia (16.0%), anaemia (10.0%), thrombocytopenia (2%), mucositis (2%) and nauseas (2%). Conclusions: These results suggest that biweekly schedule of carboplatin / docetaxel is a safe and active regimen in first line advanced NSCLC patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. L. Fírvida
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - G. Esquerdo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Amenedo
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Salgado
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - C. Llorca
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - A. González
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - E. Pérez
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - J. M. Cervera
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| | - M. Ramos
- Complejo Hospitalario de Ourense, Ourense, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital de Elda, Alicante, Spain
| |
Collapse
|
24
|
Barrajon E, Lopez A, Adrover E, Esquerdo G, Llorca C. Influence of single agent paclitaxel (TAX) schedule on the pattern of response and toxicity in patients with advanced breast and lung cancer: A systematic review. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Barrajon
- Hosp Elche, Alicante, Spain; Hosp de Alcoy, Alcoy, Spain; Hosp Alicante, Alicante, Spain; Hosp Elda, Elda, Spain
| | - A. Lopez
- Hosp Elche, Alicante, Spain; Hosp de Alcoy, Alcoy, Spain; Hosp Alicante, Alicante, Spain; Hosp Elda, Elda, Spain
| | - E. Adrover
- Hosp Elche, Alicante, Spain; Hosp de Alcoy, Alcoy, Spain; Hosp Alicante, Alicante, Spain; Hosp Elda, Elda, Spain
| | - G. Esquerdo
- Hosp Elche, Alicante, Spain; Hosp de Alcoy, Alcoy, Spain; Hosp Alicante, Alicante, Spain; Hosp Elda, Elda, Spain
| | - C. Llorca
- Hosp Elche, Alicante, Spain; Hosp de Alcoy, Alcoy, Spain; Hosp Alicante, Alicante, Spain; Hosp Elda, Elda, Spain
| |
Collapse
|
25
|
Barrajon E, Esquerdo G, Lopez A, Llorca C. Schedule dependency of 5-fluorouracil (5FU) chemotherapy in patients with advanced colorectal cancer: A systematic review. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Barrajon
- Hospital Elche, Alicante, Spain; Hospital Elda, Alicante, Spain; Hospital de la Ribera, Alzira, Valencia, Spain
| | - G. Esquerdo
- Hospital Elche, Alicante, Spain; Hospital Elda, Alicante, Spain; Hospital de la Ribera, Alzira, Valencia, Spain
| | - A. Lopez
- Hospital Elche, Alicante, Spain; Hospital Elda, Alicante, Spain; Hospital de la Ribera, Alzira, Valencia, Spain
| | - C. Llorca
- Hospital Elche, Alicante, Spain; Hospital Elda, Alicante, Spain; Hospital de la Ribera, Alzira, Valencia, Spain
| |
Collapse
|